Sponsor-Investigators

Bryan P. Schneider

BRE12-158

A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer.

Status

Closed

Cancer Types

Breast

Locations

HCRN-BRE18-334

A Phase II circulating tumor DNA enriched, genomically directed post-neoadjuvant trial for patients with residual triple negative breast cancer (PERSEVERE)

Status

Open to Accrual

Cancer Types

Breast

Locations

Advocate Aurora Research Institute (Illinois), Alabama, Aurora Health Care, Florida, Froedtert & the Medical College of Wisconsin, Georgetown Lombardi Comprehensive Cancer Center, Illinois, Indiana, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Miami Cancer Institute at Baptist Health, Inc., North Carolina, Novant Health Oncology Specialists, Texas, The University of Chicago Medicine Comprehensive Cancer Center, University of Alabama at Birmingham Comprehensive Cancer Center, University of Wisconsin Carbone Cancer Center, UT Health San Antonio MD Anderson Cancer Center, Washington, D.C., Wisconsin

BRE06-120

A Biological Sample Collection Protocol of Women With and Without Breast Cancer: Hoosier Oncology Group Study BRE06-120 for the Analytical Proteomics Team

Status

Closed

Cancer Types

Breast

Locations